Tumor-secreted adrenomedullin is a critical factor for inducing lymphangiogenesis and lymphatic enlargement through a pharmacologically tractable G-protein-coupled receptor both in primary tumor tissues and sentinel LNs, suggesting targeting of adrenomedullin signaling may provide a new avenue for inhibiting tumor progress [187]. Here, ADM is linked to neoplasm.